We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
Read MoreHide Full Article
DaVita Inc. (DVA - Free Report) reported second-quarter 2017 adjusted operating earnings of 92 cents per share that surpassed the Zacks Consensus Estimate of 90 cents. However, earnings declined from $1.01 in the year-ago quarter.
Total revenue increased from $3.72 billion year over year to approximately $3.88 billion and beat the Zacks Consensus Estimate of $3.84 billion.
Segment Update
U.S. Dialysis and Related Lab Services
Total operating revenue during the second quarter was approximately $2.33 billion, up from $2.26 billion in the year-ago quarter. However, operating income was up from $449 million in the prior-year quarter to $450 million.
Davita Medical Group (DMG)
Total operating revenue during the second quarter was $1.20 billion, up from $1.06 billion in the year-ago quarter. Also, the segment’s adjusted operating loss came in at $13 million versus the loss of $102 million in the prior-year quarter.
DaVita HealthCare Partners Inc. Price, Consensus and EPS Surprise
Total cash and cash equivalents of DaVita declined to $712.0 million as of Jun 30, from $913.2 million as of Dec 31, 2016. Cash generated from operations in the first half of 2017 was $1.01 billion compared with $945.6 million in the year-ago period. DaVita’s long-term debt was $8.91 billion, down from $8.95 billion at year-end 2016. In the reported quarter, the company repurchased 3.6 million shares of its common stock for $232 million, at an average price of $64.81 per share. The company currently has approximately $445 million outstanding Board authorized share repurchase authorization pending.
Guidance
Management projected DaVita’s consolidated operating income for 2017 in the range of $1.675–$1.775 billion. The company expects operating income of $1.565–$1.625 billion for Kidney Care. Operating income for DMG is now anticipated in the range of $110–$150 million. Operating cash flow projection for 2017 is expected at $1.750–$1.950 billion.
Zacks Rank & Stocks to Consider
DaVita carries a Zacks Rank #4 (Sell).
A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy), while Mesa Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 4.7% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 24.7% over the last three months.
Mesa Laboratories has a positive earnings surprise of 2.8% for the last four quarters. The stock has added roughly 19.4% over the last six months.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
DaVita Inc. (DVA - Free Report) reported second-quarter 2017 adjusted operating earnings of 92 cents per share that surpassed the Zacks Consensus Estimate of 90 cents. However, earnings declined from $1.01 in the year-ago quarter.
Total revenue increased from $3.72 billion year over year to approximately $3.88 billion and beat the Zacks Consensus Estimate of $3.84 billion.
Segment Update
U.S. Dialysis and Related Lab Services
Total operating revenue during the second quarter was approximately $2.33 billion, up from $2.26 billion in the year-ago quarter. However, operating income was up from $449 million in the prior-year quarter to $450 million.
Davita Medical Group (DMG)
Total operating revenue during the second quarter was $1.20 billion, up from $1.06 billion in the year-ago quarter. Also, the segment’s adjusted operating loss came in at $13 million versus the loss of $102 million in the prior-year quarter.
DaVita HealthCare Partners Inc. Price, Consensus and EPS Surprise
DaVita HealthCare Partners Inc. Price, Consensus and EPS Surprise | DaVita HealthCare Partners Inc. Quote
Financial Update
Total cash and cash equivalents of DaVita declined to $712.0 million as of Jun 30, from $913.2 million as of Dec 31, 2016. Cash generated from operations in the first half of 2017 was $1.01 billion compared with $945.6 million in the year-ago period. DaVita’s long-term debt was $8.91 billion, down from $8.95 billion at year-end 2016. In the reported quarter, the company repurchased 3.6 million shares of its common stock for $232 million, at an average price of $64.81 per share. The company currently has approximately $445 million outstanding Board authorized share repurchase authorization pending.
Guidance
Management projected DaVita’s consolidated operating income for 2017 in the range of $1.675–$1.775 billion. The company expects operating income of $1.565–$1.625 billion for Kidney Care. Operating income for DMG is now anticipated in the range of $110–$150 million. Operating cash flow projection for 2017 is expected at $1.750–$1.950 billion.
Zacks Rank & Stocks to Consider
DaVita carries a Zacks Rank #4 (Sell).
A few better-ranked medical stocks are Mesa Laboratories, Inc. (MLAB - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy), while Mesa Laboratories carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock has gained around 4.7% over the last three months.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 24.7% over the last three months.
Mesa Laboratories has a positive earnings surprise of 2.8% for the last four quarters. The stock has added roughly 19.4% over the last six months.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>